Chronic periodontitis Oral Health Chronic periodontitis
Conditions
Interventions
This study is comparing the effect of non-surgical periodontal treatment on clinical and inflammatory parameters in patients with moderate to severe chronic periodontitis and rheumatoid arthritis with
furthermore, gingival crevicular (GCF) and subgingival plaque were sampled . For RA patients, the following rheumatological parameters were determined at the same timepoints by one specialised rheumat
treated pockets were then thoroughly rinsed with 0.2% chlorhexidine digluconate solution (Corsodyl®, GlaxoSmithKline, Brentford, London, UK) and patients were instructed to rinse twice daily for 2 min
Sponsors
University of Medicine and Pharmacy Cluj-Napoca
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Moderate or severe chronic periodontitis; >30 years of age 2. =10 natural teeth present in the oral cavity 3. Full-mouth plaque scores (FMPS) =30% after oral hygiene instructions 4. No other systemic diseases or medications except for RA, which are known to influence periodontal conditions/treatment outcome (e.g. Down Syndrome, HIV, Diabetes Mellitus type 1 and 2) 5. DAS28=3.2 6. No infectious or heart diseases that need prophylactic administration of antibiotics before dental treatment 7. No liver disease; no head and neck radiation therapy
Exclusion criteria
Exclusion criteria: 1. Non-surgical periodontal therapy within the previous 12 months 2. Systemic or local use of antibiotics within the previous 3 months 3. Medication with a possible influence on the periodontium (e.g., ciclosporines, phenytoines, calcium channel blockers) 4. Pregnancy or lactation In the RA group, RA was diagnosed according to the criteria set by the American College of Rheumatology;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The decrease of CRP in the patients with rheumatoid arthritis at 3 months (The CRP level, measured as counts, was determined from blood samples in the laboratory of the Clinic of Rheumatology of the University Iuliu Hatieganu Cluj-Napoca). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes (from baseline to 6 months) of CRP at 6 months 2. ESR, measured in a similar to the CRP at 3 and 6 months in the RA-CP group 3. DAS28 at 3 and 6 months in the RA-CP group (was calculated using a formula and the ESR value), 4. BOP (calculated as %) 5. FMPS (calculated as %) 6. PD (value measured clinically at teeth in mm) 7. CAL (value measured clinically at teeth in mm) 8. Number of sites PD =4 mm incl. their changes (the sites with values of PD=4mm were counted) 9. Qualitative and quantitative analysis of microorganisms (by means of real-time polymerase chain reaction- is a laboratory test, the are parameters reported as counts of bacteria and number of patients that presented these bacteria) 10. Inflammatory markers in sulcus fluid (these are measured by ELISA Test, a laboratory test, where also the inflammatory markers are reported as counts, and the number of patients the presented the investigated inflammatory markers) at 3 and 6 months for both patient groups Unless otherwise stated, outcomes were measured at 3 months and 6 months. | — |
Countries
Romania
Outcome results
None listed